EDLПептид EDL
Glu–Asp–Leu (EDL), a defined tripeptide studied in models of kidney-cell aging. Ovagen reports list the same constituent amino acids but do not establish the sequence of the tested product.
What the studies found
Animal research · 2015
Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats
Findings for this preparation
Glomerular filtration was 543.9 µL/min with isolated EDL versus 240.8 with cisplatin alone.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model 42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.
Design Cisplatin-associated kidney injury with intact and injury controls. Urine was collected over two hours, 72 hours after cisplatin.
Important limitations
- Small rat arms and a pretreatment design. Clinical outcomes and the effects of marketed oral products were not measured. Each outcome applies to the specific arm and preparation tested.
Bulletin of Experimental Biology and Medicine. 2015;159(6):736–739. PMID 26515176. · Publication record
Animal research · 2019
Kidney polypeptide complex, EDL, AED and AEDG in aged rats
Findings for this preparation
Two-hour urine output was 4.40 mL with isolated EDL versus 3.51 mL in untreated older rats.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
Study notes · methods, sources and limitations
Participants or model 35 rats aged 20–24 months. Five randomized groups of seven.
Design Randomized animal comparison of four injected preparations and a control, with renal biochemistry and histology.
Important limitations
- The paper identifies the short peptides by sequence. The kidney complex trade name is unverified for this report. This was an aging model distinct from cisplatin injury.
Advances in Gerontology. 2019;9(1). English translation. · Publication record
Lab research · 2015
Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals
Findings for this preparation
Isolated EDL increased proliferation markers and reduced apoptosis markers in rat kidney tissue cultures. The kidney extract had a larger effect.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model Kidney explants from young and old rats
Important limitations
- Kidney tissue culture is not a cartilage model or a human renal-treatment trial. The stronger extract response illustrates why mixture effects cannot simply be assigned to one peptide.
Bull Exp Biol Med 159(1):124-127. PMID 26033601 · Indexed abstract
About EDL
Research background
Glu–Asp–Leu tripeptide studied in renal-cell aging models. It is distinct from AED/Cartalax.
- Compound class
- Peptide / preparation research
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
See preparation-specific records; human benefit not established here
Study methods
Source-specific designs and limitations below
Independent replication
Related reports are not automatically independent evidence
Source access
Linked publications; access and review scope shown per record
Safety evidence
Clinical safety, product equivalence and interactions not established by this collection
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Animal research · 2015
Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats
Glomerular filtration was 543.9 µL/min with isolated EDL versus 240.8 with cisplatin alone.
Study notes and original source
Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Injected kidney polypeptide complex, identified as Pielotax in the Russian reproduction. EDL, AED and AEDG were separate short-peptide arms.
I. I. Zamorskii, T. S. Shchudrova, N. S. Lin’kova, T. E. Nichik, V. Kh. Khavinson · Bulletin of Experimental Biology and Medicine. 2015;159(6):736–739. PMID 26515176.
Filtration rates were 433.3 with the kidney complex, 543.9 with EDL, 305.1 with AED and 469.9 with AEDG versus 240.8 µL/min with cisplatin alone. AED did not significantly improve filtration.
Results and tables
Reported findings and study design
Cisplatin-associated kidney injury with intact and injury controls. Urine was collected over two hours, 72 hours after cisplatin.
Population or model 42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.
Dose, route and schedule
Interventions were intraperitoneal once daily for four days before and three after cisplatin. Kidney complex 300 µg/kg, EDL 3 µg/kg, AED 3 µg/kg, AEDG 7 µg/kg. Cisplatin was a 6 mg/kg intraperitoneal injection 72 hours before sampling.
Protocol source ↗ · Original journal full text and Table 1. Russian reproduction identifies the branded kidney complex.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Glomerular filtration rate | 433.3 kidney complex, 543.9 EDL, 305.1 AED, 469.9 AEDG vs 240.8 µL/min with cisplatin alone | |
| Plasma creatinine | 67.43 with kidney complex vs 94.91 µmol/L with cisplatin alone | p≤0.05 |
| Diuresis over two hours | 2.62 kidney complex, 3.02 EDL, 1.81 AED, 2.89 AEDG vs 1.50 mL with cisplatin alone |
Selected Table 1 values
| Outcome | Intact | Cisplatin | Kidney complex | EDL | AED | AEDG |
|---|---|---|---|---|---|---|
| Filtration, µL/min | 502.90 | 240.8 | 433.3 | 543.9 | 305.1 | 469.9 |
| Creatinine, µmol/L | 64.90 | 94.91 | 67.43 | 68.95 | 82.60 | 77.54 |
| Urine over two hours, mL | 4.12 | 1.50 | 2.62 | 3.02 | 1.81 | 2.89 |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.
- Source reviewed
- Original journal full text and Table 1. Russian reproduction identifies the branded kidney complex.
Study limitations
- Small rat arms and a pretreatment design. Clinical outcomes and the effects of marketed oral products were not measured.
- Each outcome applies to the specific arm and preparation tested.
Reviewed 2026-11-14.
Animal research · 2019
Kidney polypeptide complex, EDL, AED and AEDG in aged rats
Two-hour urine output was 4.40 mL with isolated EDL versus 3.51 mL in untreated older rats.
Study notes and original source
Kidney polypeptide complex, EDL, AED and AEDG in aged rats
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
I. I. Zamorskii, T. S. Shchudrova, V. G. Zeleniuk, N. S. Linkova, T. E. Nichik, V. K. Khavinson · Advances in Gerontology. 2019;9(1). English translation.
Two-hour urine output was 4.25 mL with the kidney complex, 4.40 with EDL and 4.78 with AED versus 3.51 in controls. AEDG lowered filtration to 406.22 versus 516.32 µL/min.
Results and tables
Reported findings and study design
Randomized animal comparison of four injected preparations and a control, with renal biochemistry and histology.
Population or model 35 rats aged 20–24 months. Five randomized groups of seven.
Dose, route and schedule
Ten daily intraperitoneal doses: kidney polypeptide complex at 300 µg/kg, EDL or AED at 3 µg/kg each, or AEDG at 7 µg/kg. A fifth group was the control.
Protocol source ↗ · Original experimental report, English journal translation, methods and Table 1.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Two-hour diuresis | 4.25 kidney complex, 4.40 EDL, 4.78 AED, 3.94 AEDG vs 3.51 mL in controls | Table 1 marks the first three active arms significant versus control. |
| Plasma creatinine | 42.14 with kidney complex vs 57.65 µmol/L in controls | Table 1 marks this difference significant. |
| Glomerular filtration | 406.22 with AEDG vs 516.32 µL/min in controls | Table 1 marks the AEDG decrease significant. The kidney complex value of 605.63 was not marked significant. |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 35 rats aged 20–24 months. Five randomized groups of seven.
- Source reviewed
- Original experimental report, English journal translation, methods and Table 1.
Study limitations
- The paper identifies the short peptides by sequence. The kidney complex trade name is unverified for this report. This was an aging model distinct from cisplatin injury.
Reviewed 2026-11-14.
Experiment described in a patent · 2007
EDL: defined liver-regeneration peptide — RU2297239C1
The patent reports greater bilirubin reduction with EDL-containing care and a before/after ALT change.
Bilirubin · 18.6 ± 1.4 after EDL versus 22.3 ± 1.1 conventional care; baseline 27.4 ± 1.7 · Table’s blanket unit label is unsuitable for all analytes; no corrected unit invented · p<0.05 versus conventional care
Study notes and original source
EDL: defined liver-regeneration peptide — RU2297239C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Владимир Хацкелевич Хавинсон (RU), Владимир Хацкелевич Хавинсон, Евгений Иосифович Григорьев (RU), Евгений Иосифович Григорьев, Владимир Викторович Малинин (RU), Владимир Викторович Малинин, Галина Анатольевна Рыжак (RU), Галина Анатольевна Рыжак · RU2297239C1 · patent family 38036774
The patent reports greater bilirubin reduction with EDL-containing care and a before/after ALT change.
Results and tables
Reported patent results
Reported findings
The patent reports greater bilirubin reduction with EDL-containing care and a before/after ALT change.
Example 6 describes 34 chronic-hepatitis patients aged 30–56 assigned to two groups by a method called randomization. Conventional care: 15. EDL arm: 19 by subtraction. Counts for the three dose subgroups and masking are unspecified.
Population or model Example 6 describes 34 chronic-hepatitis patients aged 30–56 assigned to two groups by a method called randomization. Conventional care: 15. EDL arm: 19 by subtraction. Counts for the three dose subgroups and masking are unspecified.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Bilirubin | 18.6 ± 1.4 after EDL versus 22.3 ± 1.1 conventional care; baseline 27.4 ± 1.7 | Table’s blanket unit label is unsuitable for all analytes; no corrected unit invented · p<0.05 versus conventional care |
| ALT | 41.7 ± 2.9 after EDL versus 46.2 ± 3.8 conventional care; baseline 54.5 ± 4.9 | Marked significant versus baseline, not clearly versus conventional care · p<0.05 versus baseline |
| AST and triglycerides | AST 39.5 ± 2.3 versus baseline 40.3 ± 3.2. Triglycerides 2.4 ± 0.3 versus 2.3 ± 0.4. | The table gives no significance marker for either outcome. |
| Symptoms in the EDL arm | 89% reported less weakness with improved appetite and work capacity. 53% reported less pain. | Patent narrative. Control symptom frequencies and dose-specific results are unspecified. |
The patent prints 5 mg, 10 µg and 1 µg intramuscularly once daily for 10 days in the severe, moderate and remission subgroups, respectively. The related Eurasian filing EA010156B1 describes 10 µg daily for the entire EDL arm and repeats the same outcome table. The actual dose assignments remain unresolved. Animal Table 1 repeats all values later attributed to Ventvil in a journal paper with a different dose and animal count.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- Example 6 describes 34 chronic-hepatitis patients aged 30–56 assigned to two groups by a method called randomization. Conventional care: 15. EDL arm: 19 by subtraction. Counts for the three dose subgroups and masking are unspecified.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The EDL sequence must not be confused with AEDL Bronchogen; commercial Ovagen equivalence has not been established here.
- The patent prints 5 mg, 10 µg and 1 µg intramuscularly once daily for 10 days in the severe, moderate and remission subgroups, respectively. The related Eurasian filing EA010156B1 describes 10 µg daily for the entire EDL arm and repeats the same outcome table. The actual dose assignments remain unresolved. Animal Table 1 repeats all values later attributed to Ventvil in a journal paper with a different dose and animal count.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Animal research · 2017
Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis
Synthetic EDL reduced several measures of renal injury, including proteinuria and azotemia, and affected oxidative-stress and energy-related measures.
Study notes and original source
Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Synthetic EDL tripeptide
Zamorskii II, Shchudrova TS, Lin'kova NS, Nichik TE, Khavinson VK · Bulletin of experimental biology and medicine. 2017;163:389-393.
Synthetic EDL reduced several measures of renal injury, including proteinuria and azotemia, and affected oxidative-stress and energy-related measures.
- Population / setting
- Rats with gentamicin-associated or ischemia/reperfusion kidney injury
- Source reviewed
- PubMed-indexed abstract and bibliographic metadata checked via Europe PMC; full methods not appraised.
Study limitations
- The experiment used synthetic EDL in rat kidney injury models. Its findings do not establish a clinical effect.
Reviewed 2026-10-07.
Lab research · 2014
[Tripeptides slow down aging process in renal cell culture].
In young and aged renal cell cultures, the short peptides AED and EDL increased proliferation and SIRT6 expression while reducing the senescence-associated markers p16, p21 and p53.
Study notes and original source
[Tripeptides slow down aging process in renal cell culture].
Preparation-specific research; no equivalence inferred
Khavinson VKh, Tarnovskaia SI, Lin'kova NS, Poliakova VO, Durnova AO, Nichik TE, Kvetnoĭ IM, D'iakonov MM, Iakutseni PP. · Advances in gerontology = Uspekhi gerontologii
In young and aged renal cell cultures, the short peptides AED and EDL increased proliferation and SIRT6 expression while reducing the senescence-associated markers p16, p21 and p53.
Results and tables
Reported findings and study design
Investigators measured renal-cell proliferation and expression of aging-associated markers. They also modeled how the peptides might bind DNA.
Population or model Young and aged renal cell cultures, with a separate computational DNA interaction analysis.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Renal-cell proliferation | Increased with AED and EDL. | |
| Senescence-associated markers | p16, p21 and p53 expression decreased. SIRT6 expression increased. | |
| Modeled DNA interactions | The simulations favored binding both peptides to the minor groove of a short alternating AT sequence. |
The abstract gives neither culture concentrations nor numerical effects. The modeled binding mechanism requires direct experimental confirmation.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- Young and aged renal cell cultures, with a separate computational DNA interaction analysis.
- Source reviewed
- Original paper abstract
Study limitations
- The abstract leaves the preparation and study methods unclear.
- Related publications may share experiments; source count is not independent-study count.
Reviewed 2026-11-16.
Lab research · 2015
Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals
Isolated EDL increased proliferation markers and reduced apoptosis markers in rat kidney tissue cultures. The kidney extract had a larger effect.
Study notes and original source
Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Chalisova NI, Lin'kova NS, Nichik TE, Ryzhak AP, Dudkov AV, Ryzhak GA · Bull Exp Biol Med 159(1):124-127. PMID 26033601
Compared kidney polypeptide complex with T-31/AED and T-35/EDL. The short peptides changed proliferation and apoptosis markers, with smaller effects than the complex.
- Population / setting
- Kidney explants from young and old rats
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- Kidney tissue culture is not a cartilage model or a human renal-treatment trial.
- The stronger extract response illustrates why mixture effects cannot simply be assigned to one peptide.
Reviewed 2026-09-29.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗